CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice
CD95 (APO-/Fas) ligand (CD95L) is a member of the TNF family predominantly expressed by activated T and NK cells but also by tumors of diverse cellular origin. CD95L trimerizes surface CD95 expressed by target cells that subsequently undergo apoptosis. The role of the CD95/CD95L system in the down-r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 1, 2001
|
| In: |
The journal of immunology
Year: 2001, Volume: 166, Issue: 5, Pages: 3240-3247 |
| ISSN: | 1550-6606 |
| DOI: | 10.4049/jimmunol.166.5.3240 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4049/jimmunol.166.5.3240 Verlag, lizenzpflichtig, Volltext: https://www.jimmunol.org/content/166/5/3240 
|
| Author Notes: | Christian K. Behrens, Frederik H. Igney, Bernd Arnold, Peter Möller, Peter H. Krammer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1756032122 | ||
| 003 | DE-627 | ||
| 005 | 20220819183739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210427s2001 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.166.5.3240 |2 doi | |
| 035 | |a (DE-627)1756032122 | ||
| 035 | |a (DE-599)KXP1756032122 | ||
| 035 | |a (OCoLC)1341406131 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Behrens, Christian |e VerfasserIn |0 (DE-588)1228463697 |0 (DE-627)1750218062 |4 aut | |
| 245 | 1 | 0 | |a CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice |c Christian K. Behrens, Frederik H. Igney, Bernd Arnold, Peter Möller, Peter H. Krammer |
| 264 | 1 | |c March 1, 2001 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.04.2021 | ||
| 520 | |a CD95 (APO-/Fas) ligand (CD95L) is a member of the TNF family predominantly expressed by activated T and NK cells but also by tumors of diverse cellular origin. CD95L trimerizes surface CD95 expressed by target cells that subsequently undergo apoptosis. The role of the CD95/CD95L system in the down-regulation of an immune response (activation-induced cell death) is established. However, it is so far unclear why tumors express CD95L. To investigate whether tumors use the CD95L to down-regulate an anti-tumor immune response, we established a transgenic (tg) mouse model consisting of 1) apoptosis-resistant tumor cells, designated LKC-CD95L, which express functional CD95L and the model tumor Ag Kb; and 2) perforin knockout (PKO) anti-Kb TCR tg mice. L1210-Fas antisense expressing Kb, crmA, and CD95L (LKC-CD95L) killed CD95+ unrelated tumor targets and Con A-activated splenocytes from anti-Kb TCR tg PKO mice by a CD95L-dependent mechanism in vitro. However, we could not detect any cytotoxic activity against anti-tumor (anti-Kb) T cells in vivo. We also observed reduced growth of LKC-CD95L in nude mice and rapid rejection in anti-Kb TCR tg PKO mice. Because the tumor cells are resistant to CD95L-, TNF-α-, and TNF-related apoptosis-inducing ligand-induced apoptosis and the mice used are perforin-deficient, the involvement of these four cytotoxicity mechanisms in tumor rejection can be excluded. The histological examination of tumors grown in nude mice showed infiltration of LKC-CD95L tumors by neutrophils, whereas L1210-Fas antisense expressing Kb and crmA (LKC) tumor tissue was neutrophil-free. Chemotaxis experiments revealed that CD95L has no direct neutrophil-attractive activity. Therefore, we conclude that LKC-CD95L cells used an indirect mechanism to attract neutrophils that may cause tumor rejection. | ||
| 700 | 1 | |a Arnold, Bernd |e VerfasserIn |0 (DE-588)1112956840 |0 (DE-627)866990771 |0 (DE-576)476788021 |4 aut | |
| 700 | 1 | |a Krammer, Peter H. |d 1946- |e VerfasserIn |0 (DE-588)121766373 |0 (DE-627)081520255 |0 (DE-576)292873417 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of immunology |d Rockville, Md. : American Association of Immunologists, 1916 |g 166(2001), 5, Seite 3240-3247 |h Online-Ressource |w (DE-627)269535217 |w (DE-600)1475085-5 |w (DE-576)079963838 |x 1550-6606 |7 nnas |a CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice |
| 773 | 1 | 8 | |g volume:166 |g year:2001 |g number:5 |g pages:3240-3247 |g extent:7 |a CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice |
| 856 | 4 | 0 | |u https://doi.org/10.4049/jimmunol.166.5.3240 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.jimmunol.org/content/166/5/3240 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210427 | ||
| 993 | |a Article | ||
| 994 | |a 2001 | ||
| 998 | |g 121766373 |a Krammer, Peter H. |m 121766373:Krammer, Peter H. |d 50000 |e 50000PK121766373 |k 0/50000/ |p 5 |y j | ||
| 998 | |g 1112956840 |a Arnold, Bernd |m 1112956840:Arnold, Bernd |d 50000 |e 50000PA1112956840 |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1756032122 |e 3918290166 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice","title_sort":"CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice"}],"person":[{"given":"Christian","family":"Behrens","role":"aut","roleDisplay":"VerfasserIn","display":"Behrens, Christian"},{"family":"Arnold","given":"Bernd","display":"Arnold, Bernd","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Peter H.","family":"Krammer","role":"aut","display":"Krammer, Peter H.","roleDisplay":"VerfasserIn"}],"recId":"1756032122","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 27.04.2021"],"id":{"eki":["1756032122"],"doi":["10.4049/jimmunol.166.5.3240"]},"origin":[{"dateIssuedKey":"2001","dateIssuedDisp":"March 1, 2001"}],"name":{"displayForm":["Christian K. Behrens, Frederik H. Igney, Bernd Arnold, Peter Möller, Peter H. Krammer"]},"relHost":[{"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Association of Immunologists"}],"language":["eng"],"recId":"269535217","note":["Gesehen am 18.08.2025"],"disp":"CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout miceThe journal of immunology","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"extent":"7","text":"166(2001), 5, Seite 3240-3247","volume":"166","pages":"3240-3247","issue":"5","year":"2001"},"pubHistory":["1.1916 -"],"title":[{"title":"The journal of immunology","title_sort":"journal of immunology"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Association of Immunologists"]},"id":{"eki":["269535217"],"zdb":["1475085-5"],"issn":["1550-6606"]},"origin":[{"publisherPlace":"Oxford ; Bethesda, Md. ; Rockville, Md.","publisher":"Oxford University Press ; Soc. ; American Association of Immunologists","dateIssuedKey":"2025","dateIssuedDisp":"2025-"}]}],"physDesc":[{"extent":"7 S."}]} | ||
| SRT | |a BEHRENSCHRCD95LIGAND1200 | ||